Cervical cancer screening

• Damirova Saadet F.
• Tamara N. Bebneva

Abstract

Cervical cancer ranks fourth in mortality from cancer among women worldwide, and depends on the Level of economic development of the state. In the USA, Canada, Australia and European countries, it does not exceed 2.2 deaths per 100 thousand women. More than 85% of cervical cancer deaths occur in low- and middle-income countries. In Russia, mortality from cervical cancer has not decreased over the past 10 years and amounts to 4.4-7.1 per 100 thousand women. High morbidity also leads to serious economic losses -the average cost of treating a patient with cervical cancer is estimated at 1 million rubles.

Keywords:HPV, cervical cancer, screening, PAP-smear, liquid cytology

References

1. GLOBOCAN, IARC, 2018.

2. WHO. Human Papillomavirus (HPV) and Cervical Cancer: Fact Sheet [Electronic resource]. February 2018. URL: http://www.who.int/en/news-room/fact-sheets/detail/human-papillomavirus(hpv)-and-cervical-cancer . (in Russian)

3. Tsygankova N.G. et al. Cytological screening programs in Moscow: conclusions and successes. Presentation of the report from the International Interdisciplinary Forum “Cervix and Vulvovaginal Diseases”. Moscow, November 14-17, 2012 URL: http: // www.slideshare.net/statusprae-sens/ss-15756430 . (in Russian)

4. Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2017 global survey. Geneva: World Health Organization, 2018.

5. Bezrukov A.V., Mishukova A.A. On the organization of cytological screening for cervical cancer (for example Moscow region). Moscow, 2017.24 p. (in Russian)

6. Dikke Galina B. Prevention strategies for reducing the incidence of cervical cancer: Half-measures or new approaches? Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2016; 8: 16-23. (in Russian)

7. Sukhikh G.T., Prilepskaya V.N., ed. Cervical Cancer Prevention. A guide for doctors. Moscow: MEDpress-inform, 2012.192 р. (in Russian)

8. http://www.who.int/immunization/policy/position_papers/pp_hpv_may2017_summary.pdf?ua=1

9. World Health Organization. Immunization, Vaccines and Biologicals database as of 31 August 2018.

10. Konnon S.R.D., Soyunov M.A. Cervical cancer: prevention and screening (recent data). Akusherstvo i ginekologiya: novosti mneniya, obu-chenie [Obstetrics and Gynecology: News, Opinions, Training].. 2018; 6 (3): 72-82. (in Russian)

11. Castle P.E., Pierz А. (At Least) Once In Her Lifetime: Global Cervical Prevention // Obstet. Gynecol. Clin. N. Am. 2019. Vol. 46. Р. 107-123.

12 . World Health Organization. Human papillomavirus (HPV) and cervical cancer. 2019.

13. https://www.figo.org/news/hpv-rates-are-going-down-0016083 .

14. https://www.who.int/ru/news-room/fact-sheets/detail/human-pa-pillomavirus-(hpv)-and-cervical-cancer .

15. Small W. Jr., Bacon M.A., Bajaj A., et al. Cervical cancer: a global health crisis. Cancer. 2017; 123: 2404-12.

16. World Health Organization. Regional Office for Europe. Weekly Epidemiological Bulletin. 2014. (in Russian)

17. Cohen P.A., Jhingran A., Oaknin A., Denny L. Cervical cancer. Lancet. 2019; 393 (10167): 169-82. doi: 10.1016/S0140-6736(18)32470-X.

18. Huy N.V.Q., Le Tam M., Tram N.V.Q. The value of visual inspection with acetic acid and Pap smear in cervical cancer screening program in low resource settings - a population-based study. Gynecol Oncol Rep. 2018; 24: 18-20.

19. Sumithra S., Manonmani R. An evaluation of Pap smear, colposcopy, HPV DNA testing in screening of cervical cancer. IOSR J Dent Med Sci. (IOSR-JDMS). 2016; 15 (9): 41-8.

20. Solovyova A.V. Cervical Screening Protocol. Moscow, 2011. (in Russian)

21. Minkina G.N. Cytological screening of the cervical cancer: from the traditional PAP-test to computer technologies. Akusherstvo, ginekologiya i reproduktsiya [Obstetrics, Gynecology and Reproduction]. 2017; 11 (1): 56-63. doi: 10.17749/2313-7347.2017.11.1.056-063. (in Russian)

22. Kamineni V., Nair P., Deshpande A. Can LBC completely replace conventional Pap smear in developing countries. J Obstet Gynecol India. 2019: 69 (Issue 1): 69-76.

23. Paluszkiewicz A., Pruski D., Iwaniec K., et al. Comparison of the diagnostic value of cervical cytology and HPV HR DNA testing for the diagnosis of low-grade and high-grade squamous intraepithelial lesions across different age groups. Ginekol Pol. 2017; 88 (3): 141-6. doi: 10.5603/GP.a2017.0027.

24. Wentzensen N., Arbyn M., Berkhof J., Bower М., Canfell K., Einstein M., Farley C., Monsonego J., Franceschi S. Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer. 2017; 140: 2192200.

25. Chrysostomou A.C., Stylianou D.C., Constantinidou A., Kostrikis L.G. Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses. 2018; 10 (12): 729.

26. Arbyn M., Hillemanns P. HPV assays validated for primary cervical cancer screening. 2018. www.HPVWorld.com, 55.

27. Meijer C.J.L.M., Castle P.E., Hesselink A.T., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009; 124: 516-20.

28. Hesselink A.T., Meijer C.J.L.M., Poljak M., Berkhof J., Van Ke-menade F.J., Van Der Salm M.L., Bogaarts M., Snijders P.J.F. Clinical Validation of the Abbott RealTime High Risk HPV Assay According to the Guidelines for Human Papillomavirus DNA Test Requirements for Cervical Screening. J Clin Microbiol. 2013; 51 (7): 2409-10.

29. Huang S., Erickson B., Tang N., Mak W.B., Salituro J., Robinson J., Abravaya K. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J Clin Virol. 2009; 45. Suppl 1: S19-S23.

30. Marochko K.V., Artymuk N.V., Belokrinitskaya Т.Е., Frolova N.I. Using vaginal self-sampling devices for detection of high-risk human papillomavirus. Fundamental'naya i klinicheskaya meditsina [Fundamental and Clinical Medicine]. 2018; 3 (3): 88-92. doi: 10.23946/2500-0764-2018-3-3-78-83. (in Russian)

31. Viviano M., Tran P.L, Kenfack B., Catarino R., Akaaboune M., Te-mogne L..et al. Self-versus physician-collected samples for the follow-up of humanpapillomavirus-positive women in sub-Saharan Africa. Int J Womens Health. 2018; 10: 187-94. doi: 10.2147/IJWH.S154212.

32. Tranberg M., Bech B.H., Blaakaer J., Jensen J.S., Svanholm H., Andersen B. Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures - a randomized controlled trial. BMC Cancer. 2018; 18 (1): 273. doi: 10.1186/s12885-018-4165-4.

33. Gustavsson I., Aamio R., Berggrund M., Hedlund-Lindberg J., Strand A.S., Sanner K. et al. Randomised study shows thst repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology. Br J Cancer. 2018; 118 (6): 896904. doi: 10.1038/bjc.2017.485.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)